Daphne Caulker, NP
Family · Atlanta, GANPI 1518423771
Payments from drug & device makers
Across 104 payments — averaging $18.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$361
- Teva Pharmaceuticals USA, Inc.$275
- Novartis$129
- Johnson & Johnson$94
- UCB, Inc.$91
- Kyowa Kirin, Inc.$82
- plus $932 from 20 others
What the payments were for
- Food & beverage$1,963100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 27 | $361 |
| Teva Pharmaceuticals USA, Inc. | 11 | $275 |
| Novartis | 10 | $129 |
| Johnson & Johnson | 1 | $94 |
| UCB, Inc. | 4 | $91 |
| Kyowa Kirin, Inc. | 5 | $82 |
| Amneal Pharmaceuticals LLC | 5 | $78 |
| Biogen | 3 | $75 |
| Sunovion Pharmaceuticals Inc. | 3 | $75 |
| Avanir Pharmaceuticals, Inc. | 3 | $69 |
| Eisai Inc. | 3 | $69 |
| Amgen | 2 | $67 |
| Sanofi | 3 | $59 |
| Lilly USA, LLC | 4 | $56 |
| Currax Pharmaceuticals LLC | 4 | $51 |
| Biohaven Pharmaceuticals, Inc. | 2 | $47 |
| Lundbeck LLC | 2 | $47 |
| EMD Serono, Inc. | 2 | $43 |
| Neurelis, Inc. | 2 | $39 |
| Adamas Pharmaceuticals, Inc. | 2 | $36 |
| AstraZeneca | 1 | $25 |
| Shield Therapeutics Inc | 1 | $24 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| Acorda Therapeutics, Inc | 1 | $19 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| OWP Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$1,963 in reported general payments places this provider in the 80th percentile of 6,258 family providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Azelastine Hcl | 19 | $392 |
| Doxycycline Hyclate | 30 | $246 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 19 | $201 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 14 | $100 |
| Naproxen | 11 | $51 |
| Prednisone | 32 | $34 |
| Azithromycin | 11 | $32 |
Paid to pharmacies, not to this prescriber.
Other family in Atlanta
- Stacey TatroeAtlanta$38K
- Brandy HughesAtlanta$29K
- Cecile MartinAtlanta$23K
- Terri CowanAtlanta$21K
- Brandi Pinckney-GreeneAtlanta$18K
- Michelle SarievAtlanta$18K
- Christopher VreelandAtlanta$17K
- Angelica MillerAtlanta$15K
- Andrea Jefferson SaboorAtlanta$14K
- Allie McAllisterMarietta$299K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.